Prostate cancer screening in African American men: a review of the evidence

Author:

Kensler Kevin H1,Johnson Roman2,Morley Faith1,Albrair Mohamed34,Dickerman Barbra A5,Gulati Roman4ORCID,Holt Sarah K6,Iyer Hari S7,Kibel Adam S8,Lee Jenney R6,Preston Mark A8,Vassy Jason L910,Wolff Erika M6,Nyame Yaw A46,Etzioni Ruth4,Rebbeck Timothy R511ORCID

Affiliation:

1. Department of Population Health Sciences, Weill Cornell Medical Center , New York, NY, USA

2. Center for Global Health, Massachusetts General Hospital , Boston, MA, USA

3. Department of Global Health, University of Washington , Seattle, WA, USA

4. Division of Public Health Sciences, Fred Hutchinson Cancer Center , Seattle, WA, USA

5. Department of Epidemiology, Harvard T.H. Chan School of Public Health , Boston, MA, USA

6. Department of Urology, University of Washington , Seattle, WA, USA

7. Section of Cancer Epidemiology and Health Outcomes, Rutgers Cancer Institute of New Jersey , New Brunswick, NJ, USA

8. Department of Urology, Brigham and Women’s Hospital , Boston, MA, USA

9. VA Boston Healthcare System , Boston, MA, USA

10. Division of General Internal Medicine and Primary Care, Department of Medicine, Brigham and Women’s Hospital , Boston, MA, USA

11. Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, MA, USA

Abstract

Abstract Background Prostate cancer is the most diagnosed cancer in African American men, yet prostate cancer screening regimens in this group are poorly guided by existing evidence, given underrepresentation of African American men in prostate cancer screening trials. It is critical to optimize prostate cancer screening and early detection in this high-risk group because underdiagnosis may lead to later-stage cancers at diagnosis and higher mortality while overdiagnosis may lead to unnecessary treatment. Methods We performed a review of the literature related to prostate cancer screening and early detection specific to African American men to summarize the existing evidence available to guide health-care practice. Results Limited evidence from observational and modeling studies suggests that African American men should be screened for prostate cancer. Consideration should be given to initiating screening of African American men at younger ages (eg, 45-50 years) and at more frequent intervals relative to other racial groups in the United States. Screening intervals can be optimized by using a baseline prostate-specific antigen measurement in midlife. Finally, no evidence has indicated that African American men would benefit from screening beyond 75 years of age; in fact, this group may experience higher rates of overdiagnosis at older ages. Conclusions The evidence base for prostate cancer screening in African American men is limited by the lack of large, randomized studies. Our literature search supported the need for African American men to be screened for prostate cancer, for initiating screening at younger ages (45-50 years), and perhaps screening at more frequent intervals relative to men of other racial groups in the United States.

Funder

National Cancer Institute

National Institutes of Health

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Cancer statistics, 2024;CA: A Cancer Journal for Clinicians;2024-01

2. Can early prostate cancer screening help address mortality disparities among Black men?;JNCI: Journal of the National Cancer Institute;2023-11-10

3. Prostate-specific antigen testing rates in high-risk populations: results from the All of Us Research Program;Cancer Causes & Control;2023-10-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3